A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03038100

Recruitment Status : Completed

First Posted : January 31, 2017

Results First Posted : February 17, 2023

Last Update Posted : February 17, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

GOG Foundation

European Network of Gynaecological Oncological Trial Groups (ENGOT)

Information provided by (Responsible Party):

Hoffmann-La Roche

Study Type	Interventional
Study Design	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
Conditions	Ovarian Cancer Fallopian Tube Cancer Peritoneal Neoplasms
Interventions	Drug: Paclitaxel Drug: Carboplatin Drug: Atezolizumab Drug: Bevacizumab Drug: Atezolizumab Placebo
Enrollment	1301

Participant Flow

Recruitment Details	The study is considered "Completed" because all pre-planned study activities and analyses have been performed.
Pre-assignment Details


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Period Title: Overall Study
Started	650	651
Completed	0	0
Not Completed	650	651
Reason Not Completed
Death	289	272
Lost to Follow-up	9	10
Protocol Deviation	1	4
Withdrawal by Subject	45	51
Study Terminated By Sponsor	305	311
Physician Decision	1	3

Baseline Characteristics

Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab	Total
Arm/Group Description		Participants in the primary tumor-r...	Participants in the primary tumor-r...	Total of all reporting groups
Arm/Group Description		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.	Total of all reporting groups
Overall Number of Baseline Participants		650	651	1301
Baseline Analysis Population Description		[Not Specified]
Baseline Analysis Population Description		[Not Specified]
Age, Continuous Mean (Standard Deviation) Unit of measure: Years
	Number Analyzed	650 participants	651 participants	1301 participants
		59.3 (10.7)	58.9 (10.5)	59.1 (10.6)
Sex: Female, Male Measure Type: Count of Participants Unit of measure: Participants
	Number Analyzed	650 participants	651 participants	1301 participants
	Female	650 100.0%	651 100.0%	1301 100.0%
	Male	0 0.0%	0 0.0%	0 0.0%
Ethnicity (NIH/OMB) Measure Type: Count of Participants Unit of measure: Participants
	Number Analyzed	650 participants	651 participants	1301 participants
	Hispanic or Latino	38 5.8%	39 6.0%	77 5.9%
	Not Hispanic or Latino	598 92.0%	589 90.5%	1187 91.2%
	Unknown or Not Reported	14 2.2%	23 3.5%	37 2.8%
Race (NIH/OMB) Measure Type: Count of Participants Unit of measure: Participants
	Number Analyzed	650 participants	651 participants	1301 participants
	American Indian or Alaska Native	6 0.9%	5 0.8%	11 0.8%
	Asian	155 23.8%	150 23.0%	305 23.4%
	Native Hawaiian or Other Pacific Islander	0 0.0%	2 0.3%	2 0.2%
	Black or African American	13 2.0%	8 1.2%	21 1.6%
	White	461 70.9%	464 71.3%	925 71.1%
	More than one race	0 0.0%	0 0.0%	0 0.0%
	Unknown or Not Reported	15 2.3%	22 3.4%	37 2.8%

Outcome Measures

1.Primary Outcome


Title	Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population
Description	Investigator-assessed PFS is defined as the time from randomization to...
Description	Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Median (95% Confidence Interval) Unit of Measure: Months
	18.37 (17.22 to 19.75)	19.48 (18.14 to 20.76)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.2785
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.79 to 1.07
	Estimation Comments	[Not Specified]

2.Primary Outcome


Title	PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation
Description	Investigator-assessed PFS is defined as the time from randomization to...
Description	Investigator-assessed PFS is defined as the time from randomization to the occurrence of disease progression, as determined by the investigator from tumor assessments per RECIST v1.1, or death from any cause during the study, whichever occurs first.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	393	391
Median (95% Confidence Interval) Unit of Measure: Months
	18.50 (16.62 to 21.36)	20.83 (19.06 to 24.21)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0376
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.80
	Confidence Interval	(2-Sided) 95% 0.65 to 0.99
	Estimation Comments	[Not Specified]

3.Primary Outcome


Title	Overall Survival - ITT Population
Description	Overall Survival (OS) is defined as the time from randomization to dea...
Description	Overall Survival (OS) is defined as the time from randomization to death from any cause.
Time Frame	From randomization up to death from any cause (up to approximately 59 months)

Outcome Measure Data

Analysis Population Description

Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Median (95% Confidence Interval) Unit of Measure: Months
	46.59 (45.31 to 49.74)	50.53 ^[1] (46.26 to NA)

[1]

The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2), tumor PD-L1 status (IC0 vs. IC1/2/3), and treatment strategy (adjuvant vs. neoadjuvant).
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.3432
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.78 to 1.09
	Estimation Comments	[Not Specified]

4.Primary Outcome


Title	Overall Survival - PD-L1-Positive Subpopulation
Description	Overall Survival (OS) is defined as the time from randomization to dea...
Description	Overall Survival (OS) is defined as the time from randomization to death from any cause.
Time Frame	From randomization up to death from any cause (up to approximately 59 months)

Outcome Measure Data

Analysis Population Description

PD-L1-positive subpopulation is defined as patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	393	391
Median (95% Confidence Interval) Unit of Measure: Months
	49.15 ^[1] (45.54 to NA)	NA ^[2] (NA to NA)

[1]

The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.

[2]

67.3% of the participants were censored and the median was not reached.

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2) and treatment strategy (adjuvant vs. neoadjuvant).
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1316
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.83
	Confidence Interval	(2-Sided) 95% 0.66 to 1.06
	Estimation Comments	[Not Specified]

5.Secondary Outcome


Title	Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in ITT Population
Description	OR is defined as either a CR or PR as determined by the investigator w...
Description	OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the ITT population with measurable disease at baseline.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Measure Type: Number Unit of Measure: Percentage of participants
	88.7	92.8

6.Secondary Outcome


Title	Percentage of Participants With Objective Response (OR) Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery Group in PD-L1-Positive Population
Description	OR is defined as either a CR or PR as determined by the investigator w...
Description	OR is defined as either a CR or PR as determined by the investigator with the use of RECIST v1.1 for patients with measurable residual disease after primary surgery.
Time Frame	From randomization until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Objective Response Rate (ORR) - evaluable population is defined as primary surgery patients in the PD-L1-Positive subpopulation with measurable disease at baseline.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	393	391
Measure Type: Number Unit of Measure: Percentage of participants
	89.9	92.3

7.Secondary Outcome


Title	Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in ITT Population
Description	DOR is defined as the time interval from first occurrence of a CR or P...
Description	DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Time Frame	From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	650	651
Median (95% Confidence Interval) Unit of Measure: Months
	14.06 (13.01 to 16.62)	16.59 (14.52 to 19.09)

8.Secondary Outcome


Title	Duration of Response Assessed by Investigator as Per RECIST v1.1 - Primary Tumor-Reductive Surgery (Having Residual Measurable Disease) Group in PD-L1-Positive Population
Description	DOR is defined as the time interval from first occurrence of a CR or P...
Description	DOR is defined as the time interval from first occurrence of a CR or PR to the time of disease progression, as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever comes first for patients with measurable residual disease after primary surgery.
Time Frame	From the date of first occurrence of a confirmed complete or partial response until disease progression or death from any cause (up to approximately 55 months)

Outcome Measure Data

Analysis Population Description

Duration of Objective Response (DOR) - evaluable population is defined as patients with an objective response. The PD-L1-positive subpopulation (defined as patients in the ITT population whose PD-L1 status is IC1/2/3 at the time of randomization) who underwent primary tumor-reductive surgery.


Arm/Group Title	Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:	Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed	142	156
Median (95% Confidence Interval) Unit of Measure: Months
	13.44 (12.71 to 19.29)	17.71 (15.01 to 19.61)

9.Secondary Outcome


Title	Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group
Description	Clinically-meaningful improvement defined as a >=10-point decrease ...
Description	Clinically-meaningful improvement defined as a >=10-point decrease from the baseline score in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31).
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

Neoadjuvant Group. PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		157	152
Measure Type: Number Unit of Measure: Percentage of participants
Abdominal Pain, Presurgical/Surgery	Number Analyzed	142 participants	136 participants
Abdominal Pain, Presurgical/Surgery		54.2	50.7
Abdominal Pain, Cycle 4 Day 1	Number Analyzed	140 participants	133 participants
Abdominal Pain, Cycle 4 Day 1		36.4	32.3
Abdominal Pain, Cycle 6 Day 1	Number Analyzed	131 participants	133 participants
Abdominal Pain, Cycle 6 Day 1		55.0	48.1
Abdominal Pain, Cycle 8 Day 1	Number Analyzed	129 participants	122 participants
Abdominal Pain, Cycle 8 Day 1		64.3	54.1
Abdominal Pain, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Abdominal Pain, Cycle 12 Day 1		63.1	57.4
Abdominal Pain, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Abdominal Pain, Cycle 16 Day 1		63.5	58.0
Abdominal Pain, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Abdominal Pain, Cycle 20 Day 1		68.7	48.4
Abdominal Pain, Completion of Treatment/Early Termination Visit	Number Analyzed	143 participants	130 participants
		51.0	51.5
Abdominal Pain, Post-Treatment Follow Up 3 Months	Number Analyzed	96 participants	96 participants
Abdominal Pain, Post-Treatment Follow Up 3 Months		58.3	51.0
Abdominal Pain, Post-Treatment Follow Up 6 Months	Number Analyzed	75 participants	74 participants
Abdominal Pain, Post-Treatment Follow Up 6 Months		61.3	51.4
Abdominal Pain, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Abdominal Pain, Post-Treatment Follow Up 9 Months		60.5	50.0
Abdominal Pain, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Abdominal Pain, Post-Treatment Follow Up 12 Months		70.6	58.3
Abdominal Pain, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Abdominal Pain, Post-Treatment Follow Up 18 Months		100	50
Abdominal Pain, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Abdominal Pain, Post-Treatment Follow Up 24 Months		100	100
Bloating, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Bloating, Presurgical/Surgery		62.7	54.0
Bloating, Cycle 4 Day 1	Number Analyzed	140 participants	132 participants
Bloating, Cycle 4 Day 1		65.0	59.8
Bloating, Cycle 6 Day 1	Number Analyzed	131 participants	133 participants
Bloating, Cycle 6 Day 1		71.0	66.9
Bloating, Cycle 8 Day 1	Number Analyzed	128 participants	123 participants
Bloating, Cycle 8 Day 1		71.9	63.4
Bloating, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Bloating, Cycle 12 Day 1		68.5	63.4
Bloating, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Bloating, Cycle 16 Day 1		66.7	64.8
Bloating, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Bloating, Cycle 20 Day 1		66.3	56.5
Bloating, Completion of Treatment/ Early Termination Visit	Number Analyzed	145 participants	130 participants
Bloating, Completion of Treatment/ Early Termination Visit		62.1	58.5
Bloating, Post-Treatment Follow Up 3 Months	Number Analyzed	96 participants	96 participants
Bloating, Post-Treatment Follow Up 3 Months		57.3	53.1
Bloating, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Bloating, Post-Treatment Follow Up 6 Months		59.2	62.2
Bloating, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Bloating, Post-Treatment Follow Up 9 Months		67.4	63.2
Bloating, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Bloating, Post-Treatment Follow Up 12 Months		47.1	62.5
Bloating, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Bloating, Post-Treatment Follow Up 18 Months		66.7	50.0
Bloating, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Bloating, Post-Treatment Follow Up 24 Months		0	100

10.Secondary Outcome


Title	Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and Health Related Quality of Life (HRQoL) - Neoadjuvant Group
Description	Clinically-meaningful improvement in patient-reported function and HRQ...
Description	Clinically-meaningful improvement in patient-reported function and HRQoL during the treatment period, defined as a >=10-point increase from the baseline score on each of the functional (social, emotional, physical, role) and GHS/QoLscales of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30 (EORTC QLQ-C30).
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		157	152
Measure Type: Number Unit of Measure: Percentage of participants
Physical Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Physical Functioning, Presurgical/Surgery		35.9	33.6
Physical Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	133 participants
Physical Functioning, Cycle 4 Day 1		28.4	18.0
Physical Functioning, Cycle 6 Day 1	Number Analyzed	132 participants	133 participants
Physical Functioning, Cycle 6 Day 1		35.6	25.6
Physical Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	123 participants
Physical Functioning, Cycle 8 Day 1		37.2	36.6
Physical Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	102 participants
Physical Functioning, Cycle 12 Day 1		45.9	43.1
Physical Functioning, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Physical Functioning, Cycle 16 Day 1		42.7	42.0
Physical Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	63 participants
Physical Functioning, Cycle 20 Day 1		41.0	31.7
Physical Functioning, Completion of Treatment/Early Termination Visit	Number Analyzed	144 participants	131 participants
		38.9	34.4
Physical Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	97 participants	97 participants
Physical Functioning, Post-Treatment Follow Up 3 Months		37.1	39.2
Physical Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Physical Functioning, Post-Treatment Follow Up 6 Months		40.8	39.2
Physical Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Physical Functioning, Post-Treatment Follow Up 9 Months		32.6	50.0
Physical Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Physical Functioning, Post-Treatment Follow Up 12 Months		23.5	37.5
Physical Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Physical Functioning, Post-Treatment Follow Up 18 Months		33.3	50.0
Physical Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Physical Functioning, Post-Treatment Follow Up 24 Months		100	50
Role Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Role Functioning, Presurgical/Surgery		48.6	40.9
Role Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	133 participants
Role Functioning, Cycle 4 Day 1		38.3	22.6
Role Functioning, Cycle 6 Day 1	Number Analyzed	133 participants	134 participants
Role Functioning, Cycle 6 Day 1		45.9	33.6
Role Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	123 participants
Role Functioning, Cycle 8 Day 1		50.4	39.8
Role Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	102 participants
Role Functioning, Cycle 12 Day 1		55.9	47.1
Role Functioning, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Role Functioning, Cycle 16 Day 1		53.1	46.6
Role Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	63 participants
Role Functioning, Cycle 20 Day 1		56.6	52.4
Role Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	145 participants	131 participants
		46.9	39.7
Role Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	97 participants	97 participants
Role Functioning, Post-Treatment Follow Up 3 Months		49.5	40.2
Role Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Role Functioning, Post-Treatment Follow Up 6 Months		51.3	48.6
Role Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Role Functioning, Post-Treatment Follow Up 9 Months		53.5	52.6
Role Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Role Functioning, Post-Treatment Follow Up 12 Months		23.5	54.2
Role Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Role Functioning, Post-Treatment Follow Up 18 Months		50.0	50.0
Role Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Role Functioning, Post-Treatment Follow Up 24 Months		0	50
Social Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Social Functioning, Presurgical/Surgery		32.4	33.6
Social Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	133 participants
Social Functioning, Cycle 4 Day 1		31.2	25.6
Social Functioning, Cycle 6 Day 1	Number Analyzed	133 participants	132 participants
Social Functioning, Cycle 6 Day 1		36.8	33.3
Social Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	122 participants
Social Functioning, Cycle 8 Day 1		40.3	39.3
Social Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Social Functioning, Cycle 12 Day 1		39.6	44.6
Social Functioning, Cycle 16 Day 1	Number Analyzed	95 participants	88 participants
Social Functioning, Cycle 16 Day 1		40.0	44.3
Social Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Social Functioning, Cycle 20 Day 1		45.8	43.5
Social Functioning, Completion of Treatment/Early Termination	Number Analyzed	144 participants	130 participants
		40.3	41.5
Social Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	96 participants	96 participants
Social Functioning, Post-Treatment Follow Up 3 Months		42.7	44.8
Social Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
Social Functioning, Post-Treatment Follow Up 6 Months		46.1	35.1
Social Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
Social Functioning, Post-Treatment Follow Up 9 Months		46.5	47.4
Social Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
Social Functioning, Post-Treatment Follow Up 12 Months		29.4	54.2
Social Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
Social Functioning, Post-Treatment Follow Up 18 Months		66.7	75.0
Social Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
Social Functioning, Post-Treatment Follow Up 24 Months		0	50
Emotional Functioning, Presurgical/Surgery	Number Analyzed	142 participants	137 participants
Emotional Functioning, Presurgical/Surgery		31.7	30.7
Emotional Functioning, Cycle 4 Day 1	Number Analyzed	141 participants	132 participants
Emotional Functioning, Cycle 4 Day 1		31.2	35.6
Emotional Functioning, Cycle 6 Day 1	Number Analyzed	133 participants	131 participants
Emotional Functioning, Cycle 6 Day 1		42.1	38.2
Emotional Functioning, Cycle 8 Day 1	Number Analyzed	129 participants	123 participants
Emotional Functioning, Cycle 8 Day 1		39.5	44.7
Emotional Functioning, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
Emotional Functioning, Cycle 12 Day 1		41.4	41.6
Emotional Functioning, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
Emotional Functioning, Cycle 16 Day 1		44.8	42.0
Emotional Functioning, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
Emotional Functioning, Cycle 20 Day 1		44.6	32.3
Emotional Functioning, Completion of Treatment/Early Termination Visit	Number Analyzed	145 participants	130 participants
		33.8	33.8
Emotional Functioning, Post-Treatment Follow Up 3 months	Number Analyzed	96 participants	96 participants
Emotional Functioning, Post-Treatment Follow Up 3 months		35.4	33.3
Emotional Functioning, Post-Treatment Follow Up 6 months	Number Analyzed	76 participants	74 participants
Emotional Functioning, Post-Treatment Follow Up 6 months		30.3	33.8
Emotional Functioning, Post-Treatment Follow Up 9 months	Number Analyzed	43 participants	38 participants
Emotional Functioning, Post-Treatment Follow Up 9 months		39.5	34.2
Emotional Functioning, Post-Treatment Follow Up 12 months	Number Analyzed	17 participants	24 participants
Emotional Functioning, Post-Treatment Follow Up 12 months		29.4	29.2
Emotional Functioning, Post-Treatment Follow Up 18 months	Number Analyzed	6 participants	4 participants
Emotional Functioning, Post-Treatment Follow Up 18 months		16.7	50.0
Emotional Functioning, Post-Treatment Follow Up 24 months	Number Analyzed	1 participants	2 participants
Emotional Functioning, Post-Treatment Follow Up 24 months		0	50
GHS/HRQoL, PresurgicalSurgery	Number Analyzed	142 participants	137 participants
GHS/HRQoL, PresurgicalSurgery		44.4	46.7
GHS/HRQoL, Cycle 4 Day 1	Number Analyzed	141 participants	132 participants
GHS/HRQoL, Cycle 4 Day 1		43.3	37.1
GHS/HRQoL, Cycle 6 Day 1	Number Analyzed	133 participants	132 participants
GHS/HRQoL, Cycle 6 Day 1		51.1	47.7
GHS/HRQoL, Cycle 8 Day 1	Number Analyzed	129 participants	122 participants
GHS/HRQoL, Cycle 8 Day 1		55.0	59.0
GHS/HRQoL, Cycle 12 Day 1	Number Analyzed	111 participants	101 participants
GHS/HRQoL, Cycle 12 Day 1		60.4	61.4
GHS/HRQoL, Cycle 16 Day 1	Number Analyzed	96 participants	88 participants
GHS/HRQoL, Cycle 16 Day 1		53.1	58.0
GHS/HRQoL, Cycle 20 Day 1	Number Analyzed	83 participants	62 participants
GHS/HRQoL, Cycle 20 Day 1		59.0	61.3
GHS/HRQoL, Completion of Treatment/ Early Termination Visit	Number Analyzed	145 participants	130 participants
GHS/HRQoL, Completion of Treatment/ Early Termination Visit		46.9	53.1
GHS/HRQoL, Post-Treatment Follow Up 3 Months	Number Analyzed	95 participants	96 participants
GHS/HRQoL, Post-Treatment Follow Up 3 Months		53.7	53.1
GHS/HRQoL, Post-Treatment Follow Up 6 Months	Number Analyzed	76 participants	74 participants
GHS/HRQoL, Post-Treatment Follow Up 6 Months		48.7	41.9
GHS/HRQoL, Post-Treatment Follow Up 9 Months	Number Analyzed	43 participants	38 participants
GHS/HRQoL, Post-Treatment Follow Up 9 Months		39.5	50.0
GHS/HRQoL, Post-Treatment Follow Up 12 Months	Number Analyzed	17 participants	24 participants
GHS/HRQoL, Post-Treatment Follow Up 12 Months		17.6	41.7
GHS/HRQoL, Post-Treatment Follow Up 18 Months	Number Analyzed	6 participants	4 participants
GHS/HRQoL, Post-Treatment Follow Up 18 Months		16.7	50.0
GHS/HRQoL, Post-Treatment Follow Up 24 Months	Number Analyzed	1 participants	2 participants
GHS/HRQoL, Post-Treatment Follow Up 24 Months		0	50

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9096
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.97
	Confidence Interval	(2-Sided) 95% 0.58 to 1.62
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4662
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.21
	Confidence Interval	(2-Sided) 95% 0.73 to 2.01
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5237
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.51 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3826
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.25
	Confidence Interval	(2-Sided) 95% 0.76 to 2.07
	Estimation Comments	[Not Specified]

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9893
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.56 to 1.76
	Estimation Comments	[Not Specified]

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6892
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.89
	Confidence Interval	(2-Sided) 95% 0.49 to 1.61
	Estimation Comments	[Not Specified]

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1324
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.59
	Confidence Interval	(2-Sided) 95% 0.30 to 1.17
	Estimation Comments	[Not Specified]

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9176
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.03
	Confidence Interval	(2-Sided) 95% 0.62 to 1.70
	Estimation Comments	[Not Specified]

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7861
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.50 to 1.68
	Estimation Comments	[Not Specified]

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4539
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.31
	Confidence Interval	(2-Sided) 95% 0.65 to 2.65
	Estimation Comments	[Not Specified]

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4849
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.71
	Confidence Interval	(2-Sided) 95% 0.27 to 1.86
	Estimation Comments	[Not Specified]

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7470
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.79
	Confidence Interval	(2-Sided) 95% 0.19 to 3.34
	Estimation Comments	[Not Specified]

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0896
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	33.33
	Confidence Interval	(2-Sided) 95% -44.86 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional Functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7347
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.92
	Confidence Interval	(2-Sided) 95% 0.56 to 1.50
	Estimation Comments	[Not Specified]

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0479
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.56
	Confidence Interval	(2-Sided) 95% 0.32 to 1.00
	Estimation Comments	[Not Specified]

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0712
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.61
	Confidence Interval	(2-Sided) 95% 0.36 to 1.05
	Estimation Comments	[Not Specified]

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8168
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.56 to 1.58
	Estimation Comments	[Not Specified]

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6417
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.50 to 1.52
	Estimation Comments	[Not Specified]

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8821
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.53 to 1.72
	Estimation Comments	[Not Specified]

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2158
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.32 to 1.30
	Estimation Comments	[Not Specified]

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	[Not Specified]

Statistical Test of Hypothesis	P-Value	0.4762
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.51 to 1.37
	Estimation Comments	[Not Specified]

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7585
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.10
	Confidence Interval	(2-Sided) 95% 0.61 to 1.96
	Estimation Comments	[Not Specified]

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9985
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.52 to 1.93
	Estimation Comments	[Not Specified]

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1067
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.07
	Confidence Interval	(2-Sided) 95% 0.85 to 5.06
	Estimation Comments	[Not Specified]

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6171
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.42
	Confidence Interval	(2-Sided) 95% 0.36 to 5.61
	Estimation Comments	[Not Specified]

Statistical Analysis 27

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8084
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.41
	Confidence Interval	(2-Sided) 95% 0.08 to 23.57
	Estimation Comments	[Not Specified]

Statistical Analysis 28

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical Functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	-50.00
	Confidence Interval	(2-Sided) 95% -100.00 to 94.30
	Estimation Comments	[Not Specified]

Statistical Analysis 29

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6802
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.10
	Confidence Interval	(2-Sided) 95% 0.69 to 1.77
	Estimation Comments	[Not Specified]

Statistical Analysis 30

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3470
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.79
	Confidence Interval	(2-Sided) 95% 0.48 to 1.29
	Estimation Comments	[Not Specified]

Statistical Analysis 31

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5564
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.86
	Confidence Interval	(2-Sided) 95% 0.53 to 1.41
	Estimation Comments	[Not Specified]

Statistical Analysis 32

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5000
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.19
	Confidence Interval	(2-Sided) 95% 0.72 to 1.99
	Estimation Comments	[Not Specified]

Statistical Analysis 33

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9778
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.01
	Confidence Interval	(2-Sided) 95% 0.57 to 1.78
	Estimation Comments	[Not Specified]

Statistical Analysis 34

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6005
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.17
	Confidence Interval	(2-Sided) 95% 0.65 to 2.12
	Estimation Comments	[Not Specified]

Statistical Analysis 35

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9900
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.50 to 2.00
	Estimation Comments	[Not Specified]

Statistical Analysis 36

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2634
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.32
	Confidence Interval	(2-Sided) 95% 0.81 to 2.15
	Estimation Comments	[Not Specified]

Statistical Analysis 37

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9640
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.56 to 1.74
	Estimation Comments	[Not Specified]

Statistical Analysis 38

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4117
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.76
	Confidence Interval	(2-Sided) 95% 0.40 to 1.46
	Estimation Comments	[Not Specified]

Statistical Analysis 39

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3505
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.51
	Confidence Interval	(2-Sided) 95% 0.63 to 3.62
	Estimation Comments	[Not Specified]

Statistical Analysis 40

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2439
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.28
	Confidence Interval	(2-Sided) 95% 0.55 to 9.45
	Estimation Comments	[Not Specified]

Statistical Analysis 41

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1573
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	33.33
	Confidence Interval	(2-Sided) 95% -44.86 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 42

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Global health status/QoL, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 43

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role Functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1820
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.72
	Confidence Interval	(2-Sided) 95% 0.45 to 1.16
	Estimation Comments	[Not Specified]

Statistical Analysis 44

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0046
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.47
	Confidence Interval	(2-Sided) 95% 0.28 to 0.80
	Estimation Comments	[Not Specified]

Statistical Analysis 45

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0361
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.59
	Confidence Interval	(2-Sided) 95% 0.36 to 0.97
	Estimation Comments	[Not Specified]

Statistical Analysis 46

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.0848
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.39 to 1.06
	Estimation Comments	[Not Specified]

Statistical Analysis 47

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1224
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.37 to 1.13
	Estimation Comments	[Not Specified]

Statistical Analysis 48

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3127
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.74
	Confidence Interval	(2-Sided) 95% 0.41 to 1.33
	Estimation Comments	[Not Specified]

Statistical Analysis 49

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6065
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.42 to 1.65
	Estimation Comments	[Not Specified]

Statistical Analysis 50

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Completion of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2173
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.74
	Confidence Interval	(2-Sided) 95% 0.45 to 1.20
	Estimation Comments	[Not Specified]

Statistical Analysis 51

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1316
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.64
	Confidence Interval	(2-Sided) 95% 0.35 to 1.15
	Estimation Comments	[Not Specified]

Statistical Analysis 52

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7678
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.90
	Confidence Interval	(2-Sided) 95% 0.46 to 1.76
	Estimation Comments	[Not Specified]

Statistical Analysis 53

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7331
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.34 to 2.14
	Estimation Comments	[Not Specified]

Statistical Analysis 54

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1235
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.83
	Confidence Interval	(2-Sided) 95% 0.73 to 10.92
	Estimation Comments	[Not Specified]

Statistical Analysis 55

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	0.00
	Confidence Interval	(2-Sided) 95% -84.09 to 84.09
	Estimation Comments	[Not Specified]

Statistical Analysis 56

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Role functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

Statistical Analysis 57

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Presurgical/Surgery
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7869
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.07
	Confidence Interval	(2-Sided) 95% 0.65 to 1.78
	Estimation Comments	[Not Specified]

Statistical Analysis 58

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 4 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2502
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.73
	Confidence Interval	(2-Sided) 95% 0.43 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 59

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 6 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5066
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.50 to 1.41
	Estimation Comments	[Not Specified]

Statistical Analysis 60

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8124
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.56 to 1.59
	Estimation Comments	[Not Specified]

Statistical Analysis 61

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4656
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.23
	Confidence Interval	(2-Sided) 95% 0.70 to 2.17
	Estimation Comments	[Not Specified]

Statistical Analysis 62

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6725
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.14
	Confidence Interval	(2-Sided) 95% 0.62 to 2.12
	Estimation Comments	[Not Specified]

Statistical Analysis 63

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5780
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.82
	Confidence Interval	(2-Sided) 95% 0.41 to 1.64
	Estimation Comments	[Not Specified]

Statistical Analysis 64

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Completion of Treatment/Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7611
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.08
	Confidence Interval	(2-Sided) 95% 0.66 to 1.76
	Estimation Comments	[Not Specified]

Statistical Analysis 65

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7588
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.09
	Confidence Interval	(2-Sided) 95% 0.62 to 1.94
	Estimation Comments	[Not Specified]

Statistical Analysis 66

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1428
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.60
	Confidence Interval	(2-Sided) 95% 0.30 to 1.19
	Estimation Comments	[Not Specified]

Statistical Analysis 67

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9802
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95% 0.41 to 2.39
	Estimation Comments	[Not Specified]

Statistical Analysis 68

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1967
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.34
	Confidence Interval	(2-Sided) 95% 0.63 to 8.70
	Estimation Comments	[Not Specified]

Statistical Analysis 69

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4795
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Difference in Proportion of Respnders
	Estimated Value	8.33
	Confidence Interval	(2-Sided) 95% -69.28 to 85.94
	Estimation Comments	[Not Specified]

Statistical Analysis 70

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Social functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	50.00
	Confidence Interval	(2-Sided) 95% -94.30 to 100.00
	Estimation Comments	[Not Specified]

11.Secondary Outcome


Title	Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group
Description	Percentage of participants with clinical improvement, defined as >=...
Description	Percentage of participants with clinical improvement, defined as >= 10-point increase from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.
Time Frame	From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.

Outcome Measure Data

Analysis Population Description

PRO-evaluable population is defined as patients in the ITT population with a baseline and >=1 post-baseline PRO assessment.


Arm/Group Title		Placebo With Paclitaxel, Carboplatin and Bevacizumab	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Arm/Group Description:		Participants in the primary tumor-r...	Participants in the primary tumor-r...
Arm/Group Description:		Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.	Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
Overall Number of Participants Analyzed		473	473
Measure Type: Number Unit of Measure: Percentage of participants
Physical Functioning, Cycle 3 Day 1	Number Analyzed	456 participants	444 participants
Physical Functioning, Cycle 3 Day 1		22.6	19.8
Physical Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	423 participants
Physical Functioning, Cycle 5 Day 1		23.7	21.3
Physical Functioning, Cycle 8 Day 1	Number Analyzed	414 participants	403 participants
Physical Functioning, Cycle 8 Day 1		28.7	27.0
Physical Functioning, Cycle 12 Day 1	Number Analyzed	378 participants	358 participants
Physical Functioning, Cycle 12 Day 1		35.4	32.4
Physical Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Physical Functioning, Cycle 16 Day 1		32.1	34.3
Physical Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	234 participants
Physical Functioning, Cycle 20 Day 1		34.8	32.5
Physical Functioning, Completion of Treatment/Early Termination Visit	Number Analyzed	370 participants	366 participants
		32.4	30.3
Physical Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Physical Functioning, Post-Treatment Follow Up 3 Months		35.7	28.4
Physical Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Physical Functioning, Post-Treatment Follow Up 6 Months		32.7	31.1
Physical Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Physical Functioning, Post-Treatment Follow Up 9 Months		34.5	27.6
Physical Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Physical Functioning, Post-Treatment Follow Up 12 Months		37.8	24.1
Physical Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Physical Functioning, Post-Treatment Follow Up 18 Months		42.9	18.8
Physical Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Physical Functioning, Post-Treatment Follow Up 24 Months		0	16.7
Role Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
Role Functioning, Cycle 3 Day 1		42.6	40.9
Role Functioning, Cycle 5 Day 1	Number Analyzed	438 participants	422 participants
Role Functioning, Cycle 5 Day 1		42.9	38.9
Role Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	401 participants
Role Functioning, Cycle 8 Day 1		47.5	45.9
Role Functioning, Cycle 12 Day 1	Number Analyzed	377 participants	358 participants
Role Functioning, Cycle 12 Day 1		50.1	50.6
Role Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	311 participants
Role Functioning, Cycle 16 Day 1		52.0	50.8
Role Functioning, Cycle 20 Day 1	Number Analyzed	253 participants	233 participants
Role Functioning, Cycle 20 Day 1		53.8	51.5
Role Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	370 participants	367 participants
		48.4	46.6
Role Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	235 participants	236 participants
Role Functioning, Post-Treatment Follow Up 3 Months		54.0	45.3
Role Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	147 participants	164 participants
Role Functioning, Post-Treatment Follow Up 6 Months		55.1	43.9
Role Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Role Functioning, Post-Treatment Follow Up 9 Months		57.1	38.8
Role Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Role Functioning, Post-Treatment Follow Up 12 Months		60	27.6
Role Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Role Functioning, Post-Treatment Follow Up 18 Months		50	43.8
Role Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Role Functioning, Post-Treatment Follow Up 24 Months		50	16.7
Social Functioning, Cycle 3 Day 1	Number Analyzed	455 participants	442 participants
Social Functioning, Cycle 3 Day 1		30.1	31.4
Social Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Social Functioning, Cycle 5 Day 1		32.6	32.0
Social Functioning, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
Social Functioning, Cycle 8 Day 1		37.8	38.7
Social Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Social Functioning, Cycle 12 Day 1		42.6	41.2
Social Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Social Functioning, Cycle 16 Day 1		43.5	48.7
Social Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Social Functioning, Cycle 20 Day 1		45.6	50.0
Social Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	367 participants	367 participants
		40.6	40.1
Social Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Social Functioning, Post-Treatment Follow Up 3 Months		42.7	41.1
Social Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Social Functioning, Post-Treatment Follow Up 6 Months		43.2	34.1
Social Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Social Functioning, Post-Treatment Follow Up 9 Months		50.0	36.7
Social Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Social Functioning, Post-Treatment Follow Up 12 Months		62.2	36.2
Social Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Social Functioning, Post-Treatment Follow Up 18 Months		57.1	43.8
Social Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Social Functioning, Post-Treatment Follow Up 24 Months		100	50
Emotional Functioning, Cycle 3 Day 1	Number Analyzed	454 participants	443 participants
Emotional Functioning, Cycle 3 Day 1		29.7	28.4
Emotional Functioning, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
Emotional Functioning, Cycle 5 Day 1		30.3	30.3
Emotional Functioning, Cycle 8 Day 1	Number Analyzed	412 participants	403 participants
Emotional Functioning, Cycle 8 Day 1		32.3	33.0
Emotional Functioning, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
Emotional Functioning, Cycle 12 Day 1		34.6	36.1
Emotional Functioning, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
Emotional Functioning, Cycle 16 Day 1		31.8	35.9
Emotional Functioning, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
Emotional Functioning, Cycle 20 Day 1		35.3	36.8
Emotional Functioning, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
		27.7	28.6
Emotional Functioning, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
Emotional Functioning, Post-Treatment Follow Up 3 Months		29.1	27.5
Emotional Functioning, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
Emotional Functioning, Post-Treatment Follow Up 6 Months		30.4	37.8
Emotional Functioning, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
Emotional Functioning, Post-Treatment Follow Up 9 Months		38.1	33.7
Emotional Functioning, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
Emotional Functioning, Post-Treatment Follow Up 12 Months		44.4	34.5
Emotional Functioning, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
Emotional Functioning, Post-Treatment Follow Up 18 Months		42.9	31.3
Emotional Functioning, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
Emotional Functioning, Post-Treatment Follow Up 24 Months		50.0	16.7
GHS/OoL, Cycle 3 Day 1	Number Analyzed	455 participants	443 participants
GHS/OoL, Cycle 3 Day 1		32.3	34.5
GHS/OoL, Cycle 5 Day 1	Number Analyzed	439 participants	422 participants
GHS/OoL, Cycle 5 Day 1		33.0	31.0
GHS/OoL, Cycle 8 Day 1	Number Analyzed	413 participants	403 participants
GHS/OoL, Cycle 8 Day 1		39.5	38.7
GHS/OoL, Cycle 12 Day 1	Number Analyzed	376 participants	357 participants
GHS/OoL, Cycle 12 Day 1		41.5	43.4
GHS/OoL, Cycle 16 Day 1	Number Analyzed	333 participants	312 participants
GHS/OoL, Cycle 16 Day 1		42.9	42.9
GHS/OoL, Cycle 20 Day 1	Number Analyzed	252 participants	234 participants
GHS/OoL, Cycle 20 Day 1		42.5	46.2
GHS/OoL, Completion of Treatment/ Early Termination Visit	Number Analyzed	368 participants	367 participants
GHS/OoL, Completion of Treatment/ Early Termination Visit		38.0	34.9
GHS/OoL, Post-Treatment Follow Up 3 Months	Number Analyzed	234 participants	236 participants
GHS/OoL, Post-Treatment Follow Up 3 Months		40.6	38.6
GHS/OoL, Post-Treatment Follow Up 6 Months	Number Analyzed	148 participants	164 participants
GHS/OoL, Post-Treatment Follow Up 6 Months		39.2	34.1
GHS/OoL, Post-Treatment Follow Up 9 Months	Number Analyzed	84 participants	98 participants
GHS/OoL, Post-Treatment Follow Up 9 Months		39.3	35.7
GHS/OoL, Post-Treatment Follow Up 12 Months	Number Analyzed	45 participants	58 participants
GHS/OoL, Post-Treatment Follow Up 12 Months		40.0	32.8
GHS/OoL, Post-Treatment Follow Up 18 Months	Number Analyzed	14 participants	16 participants
GHS/OoL, Post-Treatment Follow Up 18 Months		42.9	18.8
GHS/OoL, Post-Treatment Follow Up 24 Months	Number Analyzed	2 participants	6 participants
GHS/OoL, Post-Treatment Follow Up 24 Months		100	33.3

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6651
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.94
	Confidence Interval	(2-Sided) 95% 0.70 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.9927
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95% 0.75 to 1.34
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8209
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.03
	Confidence Interval	(2-Sided) 95% 0.77 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6507
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.07
	Confidence Interval	(2-Sided) 95% 0.79 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2596
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.21
	Confidence Interval	(2-Sided) 95% 0.87 to 1.67
	Estimation Comments	[Not Specified]

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6532
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.09
	Confidence Interval	(2-Sided) 95% 0.75 to 1.58
	Estimation Comments	[Not Specified]

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Completion Of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7592
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.05
	Confidence Interval	(2-Sided) 95% 0.76 to 1.45
	Estimation Comments	[Not Specified]

Statistical Analysis 8

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7424
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.62 to 1.40
	Estimation Comments	[Not Specified]

Statistical Analysis 9

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1912
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.37
	Confidence Interval	(2-Sided) 95% 0.85 to 2.19
	Estimation Comments	[Not Specified]

Statistical Analysis 10

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5526
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.83
	Confidence Interval	(2-Sided) 95% 0.45 to 1.53
	Estimation Comments	[Not Specified]

Statistical Analysis 11

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3609
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.69
	Confidence Interval	(2-Sided) 95% 0.32 to 1.52
	Estimation Comments	[Not Specified]

Statistical Analysis 12

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.7527
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.80
	Confidence Interval	(2-Sided) 95% 0.20 to 3.23
	Estimation Comments	[Not Specified]

Statistical Analysis 13

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Emotional functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	-33.33
	Confidence Interval	(2-Sided) 95% -100.00 to 75.44
	Estimation Comments	[Not Specified]

Statistical Analysis 14

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 3 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3177
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95% 0.62 to 1.17
	Estimation Comments	[Not Specified]

Statistical Analysis 15

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 5 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.4184
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.63 to 1.21
	Estimation Comments	[Not Specified]

Statistical Analysis 16

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 8 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5710
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.91
	Confidence Interval	(2-Sided) 95% 0.67 to 1.24
	Estimation Comments	[Not Specified]

Statistical Analysis 17

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 12 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3973
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95% 0.65 to 1.19
	Estimation Comments	[Not Specified]

Statistical Analysis 18

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 16 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5163
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.12
	Confidence Interval	(2-Sided) 95% 0.80 to 1.55
	Estimation Comments	[Not Specified]

Statistical Analysis 19

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Cycle 20 Day 1
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.6897
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.93
	Confidence Interval	(2-Sided) 95% 0.64 to 1.35
	Estimation Comments	[Not Specified]

Statistical Analysis 20

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Completion Of Treatment/ Early Termination Visit
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.5735
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.91
	Confidence Interval	(2-Sided) 95% 0.67 to 1.25
	Estimation Comments	[Not Specified]

Statistical Analysis 21

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 3 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1414
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.75
	Confidence Interval	(2-Sided) 95% 0.50 to 1.10
	Estimation Comments	[Not Specified]

Statistical Analysis 22

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 6 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.8655
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.96
	Confidence Interval	(2-Sided) 95% 0.59 to 1.55
	Estimation Comments	[Not Specified]

Statistical Analysis 23

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 9 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.3017
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.72
	Confidence Interval	(2-Sided) 95% 0.38 to 1.35
	Estimation Comments	[Not Specified]

Statistical Analysis 24

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 12 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.2325
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.60
	Confidence Interval	(2-Sided) 95% 0.26 to 1.39
	Estimation Comments	[Not Specified]

Statistical Analysis 25

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 18 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis

Statistical Test of Hypothesis	P-Value	0.1717
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]

Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	0.33
	Confidence Interval	(2-Sided) 95% 0.06 to 1.69
	Estimation Comments	[Not Specified]

Statistical Analysis 26

Statistical Analysis Overview	Comparison Group Selection	Placebo With Paclitaxel, Carboplatin and Bevacizumab, Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
	Comments	Physical functioning, Post-Treatment Follow Up 24 Months
	Type of Statistical Test	Superiority
	Comments	Stratified Analsyis

Method of Estimation	Estimation Parameter	Difference in Proportion of Responders
	Estimated Value	16.67
	Confidence Interval	(2-Sided) 95% -46.49 to 79.82
	Estimation Comments	[Not Specified]